Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results

Basit Öğe Kaydı
dc.authoridUslu, Sadettin/0000-0001-6266-2454
dc.authoridAkar, Servet/0000-0002-3734-1242
dc.authoridKoken Avsar, Aydan/0000-0003-4149-621X
dc.authorwosidUslu, Sadettin/ABE-8560-2020
dc.contributor.authorUslu, Sadettin
dc.contributor.authorGulle, Semih
dc.contributor.authorUrak, Ozkan
dc.contributor.authorSen, Gercek
dc.contributor.authorDalkilic, Ediz
dc.contributor.authorSenel, Soner
dc.contributor.authorAkar, Servet
dc.date.accessioned2024-08-04T20:56:04Z
dc.date.available2024-08-04T20:56:04Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjectives: This study aims to investigate the effect of age on disease activity and biological treatment in patients with ankylosing spondylitis (AS). Patients and methods: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined as <60 years of age (n=610), and those aged >= 60 years (n=201) were recorded as elderly patients. Demographic, clinical, and laboratory characteristics, along with disease activity markers and other follow-up parameters, as well as current and prior treatments, were electronically recorded during each visit using open -source software. Results: The mean age of the elderly patients was 67 +/- 5.8 years, while the mean age of the younger patients was 49.2 +/- 10.9 years. Male predominance was lower in the older AS group compared to the younger AS group (p=0.002). During follow-up period, 397 patients (comprising 318 young and 79 elderly individuals) had a history of using at least one biological disease -modifying agent (bDMARD). There was no significant difference between the groups in terms of DMARD and bDMARD-use distributions. First tumor necrosis factor inhibitor (TNFi) retention rates were found to be similar in both groups over 10 years of follow-up. Adverse events were found to be similar in young (19.9%) and elderly (26.8%) AS patients. Conclusion: Research in the TURKBIO cohort reveals that both older and younger patients with AS exhibited similar disease activity levels with comparable treatment approaches. Moreover, the results of TNFi treatments in elderly patients were the same as those observed in younger patients, with no notable increase in safety concerns.en_US
dc.description.sponsorshipRheumatic Diseases Follow-up Association (ROHIDER) in Izmiren_US
dc.description.sponsorshipIt is sponsored by the Rheumatic Diseases Follow-up Association (ROHIDER) in Izmir.en_US
dc.identifier.doi10.46497/ArchRheumatol.2024.10391
dc.identifier.issn2618-6500
dc.identifier.pmid38933720en_US
dc.identifier.scopus2-s2.0-85194879304en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.46497/ArchRheumatol.2024.10391
dc.identifier.urihttps://hdl.handle.net/11616/102025
dc.identifier.wosWOS:001188581400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish League Against Rheumatismen_US
dc.relation.ispartofArchives of Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdverse eventen_US
dc.subjectankylosing spondylitisen_US
dc.subjectbiological disease-modifying anti-rheumatic drugen_US
dc.subjectgeriatricen_US
dc.subjecttumor necrosis factor inhibitoren_US
dc.titleBiological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data resultsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu